E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular...
Secondary HyperparathyroidismChronic Kidney DiseaseThe purpose of this study is to evaluate the effects of cinacalcet (cinacalcet HCl or Sensipar®/Mimpara®) on cardiovascular events and death in chronic kidney disease (CKD) patients with secondary hyperparathyroidism (HPT) who are receiving dialysis.
Safety and Efficacy of Iron Sucrose in Children
AnemiaChronic Kidney DiseaseComparison of three potential iron sucrose maintenance regimens in pediatric chronic kidney disease (CKD) patients
Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients
Kidney FailureChronicThe purpose of the investigators study is to assess the impact of therapy with Pentoxifylline (PTF), a nonspecific phosphodiesterase inhibitor, on kidney function in patients at high-risk for progression to end-stage renal disease. The investigators hypothesize that therapy with Pentoxifylline will slow progression of kidney disease over time.
Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome
Heart FailureCongestive2 moreErythropoietin (EPO) treatment in patients with the severe cardiorenal syndrome increases cardiac performance and decreases progression of renal failure by dampening the main driving forces of the cardiorenal syndrome in part via non-erythropoietic pathways. I. Does EPO administration to patients with the severe cardiorenal syndrome increase cardiac performance and decrease progression of renal disease? II. Does EPO treatment affect the main driving forces of the cardiorenal connection, that is, dampen the activated renin-angiotensin system (RAS), attenuate increased reactive oxygen species (ROS), normalize increased sympathetic activity, and decrease inflammation? III. Does EPO treatment positively affect the cell function of patients with the cardiorenal syndrome: are gene expression signatures of leukocytes positively influenced by EPO treatment, does EPO shift the Jak/STAT pathway to a less pro-inflammatory profile in monocytes, and are function and number of endothelial progenitor cells (EPCs) affected by treatment with EPO in the cardiorenal syndrome? IV. Can the direct actions of EPO be differentiated from the effects on hemoglobin levels?
Dialysis Clinical Outcomes Revisited (DCOR) Trial
Chronic Kidney DiseaseThis is a randomized, open-label, parallel-design study to be conducted at 75 centers within the United States. The study will be described to hemodialysis patients. Informed consent will be obtained and the inclusion/exclusion criteria reviewed. Eligible patients will be randomized to receive either Renagel or a calcium-based binder. Starting from the randomization date, mortality data including survival, death date and cause of death (vital status information) and morbidity data including hospitalization date will be recorded for all patients. These data will be collected until the end of the study (December 31, 2004, ± 2 weeks). Patients completing or terminating from the study will return to the phosphate binder prescribed by their usual healthcare provider.
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects...
Renal InsufficiencyChronicThe objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis
Chronic Kidney DiseaseKidney DiseaseThe proposed study is designed to test a novel dosing paradigm that would facilitate the treatment of anemia in CKD patients not on dialysis. Anemic patients who are not currently receiving ESA therapy will be dosed with darbepoetin alfa Q2W for 18 weeks.
EPO Deep Tank in Dialysis Subjects
Chronic Kidney DiseaseSubject incidence of adverse events
Efficacy of Pentoxifylline on Chronic Kidney Disease
Chronic Kidney DiseaseTo study whether pentoxifylline has additive renoprotective effect in patients taking ARB
Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects...
Kidney FailureChronicTo show non-inferiority in the incidence rates of elevated calcium-phosphorus product between two treatment groups: 1) a group having an initial dose based on baseline PTH (baseline iPTH/80) and 2) a group having a starting dose based on body weight (0.04 mcg/kg).